The research was conducted at the Rothschild Foundation Hospital in Paris and presented at the European Society of Minimally Invasive Neurological Therapy (ESMINT) Congress in Nice, France, the company said.

The research showed 94% technical and 95.7% clinical success for CorPath GRX. Of the 117 patients who underwent embolism with the system, 64.5% experienced "complete obliteration of the aneurysm" and 78.2% of study participants showed no symptoms after the procedure, according to Corindus.

Patients will be tracked for six months to monitor long-term outcomes, the company said.